Physician profile
Steven Moskowitz
NPI 1003968629
$2,792.79
in general payments reported to CMS, 2019-2025
29 companies · $453 in 2025
The $453 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $214 · 2021: $334 · 2022: $488 · 2023: $440 · 2024: $457 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,350.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $367.95 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Kaleo, INC. | $301.22 | 2021-2024 | Auvi-Q |
| Cranial Technologies, INC | $243.47 | 2019-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $195.08 | 2019-2025 | Vaxneuvance, Gardasil 9, M-M-R II |
| Sanofi Pasteur INC. | $172.81 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $157.86 | 2019-2022 | |
| Aytu Biopharma, INC. | $143.68 | 2020-2023 | |
| Neos Therapeutics, LP | $138.43 | 2019-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Covis Pharma Gmbh | $137.99 | 2021-2023 | |
| Pfizer INC. | $122.93 | 2022-2025 | |
| Alk-Abello, INC | $112.31 | 2024-2025 | Odactra, Grastek, Ragwitek |
| Genentech USA, INC. | $90.16 | 2019-2021 | |
| Ars Pharmaceuticals Operations, INC. | $87.95 | 2025 | Neffy |
| Astrazeneca Pharmaceuticals LP | $58.07 | 2019-2023 | Flumist Quadrivalent |
| Tris Pharma INC | $56.35 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $55.22 | 2021-2022 | |
| Seqirus USA INC | $46.49 | 2022-2025 | Flucelvax, Flucelvax Quadrivalent |
| Baxter Healthcare | $44.50 | 2022 | |
| Ironshore Pharmaceuticals INC. | $43.24 | 2019-2024 | |
| Rhodes Pharmaceuticals L.P. | $40.32 | 2019 | |
| Corium, LLC | $34.08 | 2022-2024 | Azstarys |
| Sobi, INC | $26.12 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $23.32 | 2025 | |
| Biomarin Pharmaceutical INC. | $18.98 | 2022 | |
| Qiagen, LLC | $15.92 | 2022 | |
| Phadia US INC. | $15.89 | 2024 | Immunocap |
| Kowa Pharmaceuticals America, INC. | $14.91 | 2025 | Zoryve |
| Dermira, INC. | $14.41 | 2019 | |
| Adlon Therapeutics L.P. | $13.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Moskowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.